Retinal Vein Occlusion Clinical Trials
Here are the 2 most popular medical studies for retinal vein occlusion
Stem Cell Therapy
Stem Cell Therapy for Central Retinal Vein Occlusion
This trial is testing whether a stem cell therapy can improve vision in people with central retinal vein occlusion. Half the participants will receive the therapy immediately, and the other half will receive it 6 months later.
Popular filter options for retinal vein occlusion trials
RVO Clinical Trials
View 7 RVO medical studies.
Corticosteroid
Dexamethasone intravitreal implant +1 More for Retinal Vein Occlusion
This study seeks to compare dexamethasone implant with rescue intravitreal ranibizumab to monthly intravitreal ranibizumab for the treatment of macular edema secondary to branch or central retinal vein occlusion. This is based on the null hypothesis that dexamethasone implant with rescue ranibizumab has inferior best corrected visual acuity at six months compared to monthly ranibizumab alone.
Retinal Vein Occlusion Clinical Trials With No Placebo
View 13 retinal vein occlusion medical studies that do not have a placebo group.
Corticosteroid
Ozurdex +2 More for Macular Edema
CRVO occurs when the vessels in the back of the eye become blocked. This creates a dangerous condition because the vessels are weak and prone to leakage. This results in the development of macular edema. Previous studies have shown that inflammatory mediators and growth factors, such as vascular endothelial growth factor (VEGF), are elevated in patients with macular edema associated with CRVO. Ozurdex® is approved by the Food and Drug Administration (FDA) and is available by prescription for macular edema following CRVO and branch retinal vein occlusion (BRVO). It is also indicated for the treatment of non-infectious uveitis affecting the posterior segment of the eye. The approved dosage is 0.7 mg. Ranibizumab (Lucentis®) is approved by the Food and Drug Administration (FDA) and is available by prescription for other eye disorders, such as wet age-related macular degeneration (AMD), macular edema following CRVO or BRVO, and diabetic macular edema (DME). The approved dosage for wet AMD and macular edema following CRVO/BROV is 0.5 mg given monthly. The approved dosage for DME is 0.3 mg given monthly. Dr. Gonzalez is conducting an investigational study on the safety and effectiveness of treating CRVO-associated Macular Edema with a combination of 0.7 mg of Ozurdex® and 0.5 mg Lucentis®, given as separate injections into the eye.
Frequently Asked Questions
Introduction to retinal vein occlusion
What are the top hospitals conducting retinal vein occlusion research?
Advancements in the treatment of retinal vein occlusion, a condition that can lead to vision loss, are being made by top hospitals around the world. In Winter Haven, Florida, the Center for Retina and Macular Disease is actively involved in two clinical trials focused on retinal vein occlusion. With a total of four trials conducted thus far since their first recorded trial in 2013, this center is committed to exploring innovative approaches to tackle this eye disorder. Meanwhile, over at St Michael's Hospital in Toronto, Canada's Department of Ophthalmology has also delved into the realm of retinal vein occlusion research. They currently have two active trials underway and have contributed two previous trials since embarking on their journey in 2017.
Across coasts lies Retina Consultants of Orange County located in Fullerton; they are currently engaged with one ongoing trial while having already conducted a noteworthy count of four investigations after initiating their pioneering study as recent as 2018. Excitingly, Mountain View | Ophthalmology situated at Loma Linda enters this field with promising potential as they initiate one groundbreaking investigation that focuses primarily on retinal vein occlusion starting as soon as2023 accompanied by South Coast Retina Center based out Long Beach who join them side-by-side conducting similar exploration commencing from same year focusing entirely upon such cases.
These dedicated hospitals exemplify global efforts to find effective treatments for retinal vein occlusion and improve patients' lives through cutting-edge research initiatives. By pushing boundaries and investigating new possibilities within the field of ophthalmology across different locations worldwide these institutions strive towards attaining breakthroughs which ultimately pave way towards brighter future where visual impairments caused due to retinol veins stop being threatening issues due to availability revolutionary remedies
Which are the best cities for retinal vein occlusion clinical trials?
When it comes to retinal vein occlusion clinical trials, several cities emerge as leading research hubs. Hagerstown, Maryland tops the list with 4 active trials focusing on treatments like Higher Dose Regimen 1 and bevacizumab. Baltimore, Maryland follows closely behind with 3 ongoing studies exploring Higher Dose Regimen 1 and other interventions. Philadelphia, Pennsylvania also boasts 3 active trials investigating Higher Dose Regimen 1 and dexamethasone intravitreal implant among other potential therapies. Meanwhile, San Antonio, Texas and Toronto, Ontario each contribute their own set of promising studies in the field of retinal vein occlusion treatment. These cities serve as valuable locations for individuals seeking participation in cutting-edge clinical trials that may pave the way for improved care options for this condition.
Which are the top treatments for retinal vein occlusion being explored in clinical trials?
The exciting field of retinal vein occlusion research is witnessing active exploration of various treatments in clinical trials. One standout contender is aflibercept, which has shown promise in addressing this condition. Currently, there is one ongoing trial dedicated to evaluating its effectiveness for retinal vein occlusion. Since its listing in 2012, aflibercept has been the subject of nine clinical trials focused on this specific condition. As researchers delve deeper into these studies, they are inching closer towards finding innovative solutions for patients affected by retinal vein occlusions.
What are the most recent clinical trials for retinal vein occlusion?
Exciting advancements in the field of retinal vein occlusion are emerging through recent clinical trials. These studies offer hope for improved treatment options and better outcomes for patients. Notably, a Phase 3 trial has investigated the efficacy of a higher dose regimen as a potential approach to managing retinal vein occlusion. Another promising development is the Phase 2 trial evaluating the use of ANXV - active at a dosage of 2 mg. Furthermore, ongoing research explores the effectiveness of bevacizumab and aflibercept in treating this condition, with Phase 3 and Phase 4 trials respectively seeking to validate their benefits. Additionally, an innovative Phase 1 study examines episcleral celecoxib's potential role in mitigating retinal vein occlusion symptoms. Collectively, these endeavors bring us closer to enhancing patient care for individuals affected by retinal vein occlusion while shedding light on new treatment possibilities.
What retinal vein occlusion clinical trials were recently completed?
Several notable clinical trials focusing on retinal vein occlusion have recently reached completion, demonstrating promising advancements in the field. Hoffmann-La Roche sponsored two significant trials investigating Faricimab, with both studies concluding successfully in March 2021. Another noteworthy trial involved MHU650, supported by Novartis Pharmaceuticals, which concluded in December 2020. Furthermore, Kodiak Sciences Inc completed a trial for KSI-301 in September 2020. Although slightly older but still worth mentioning is the Minocycline study conducted by the National Eye Institute (NEI), which was finalized in March 2012. These collective efforts showcase ongoing research and innovation aimed at enhancing treatment options for individuals affected by retinal vein occlusion.